IMMUNITYBIO, INC. Gain (Loss) on Investments
IMMUNITYBIO, INC. (IBRX) reported Gain (Loss) on Investments of $3.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnInvestments · last filed 2026-08-04
- IMMUNITYBIO, INC. gain (loss) on investments for the quarter ending 2026-06-30 was $3.15M, a 173.63% increase year-over-year.
- IMMUNITYBIO, INC. gain (loss) on investments for the quarter ending 2026-03-31 was $2.31M, a 160.88% increase year-over-year.
- IMMUNITYBIO, INC. gain (loss) on investments for the quarter ending 2025-12-31 was $2.30M, a 93.60% increase year-over-year.
- IMMUNITYBIO, INC. gain (loss) on investments for the quarter ending 2025-09-30 was $2.07M, a 14.96% increase year-over-year.
- IMMUNITYBIO, INC. gain (loss) on investments for fiscal 2025 was $6.41M, a 19.69% decline from fiscal 2024.
- IMMUNITYBIO, INC. gain (loss) on investments for fiscal 2024 was $7.97M, a 605.13% increase from fiscal 2023.
- IMMUNITYBIO, INC. gain (loss) on investments for fiscal 2023 was $1.13M.
- IMMUNITYBIO, INC. gain (loss) on investments for fiscal 2022 was -$3.09M.
| Period end | Gain (Loss) on Investments 3 month | Gain (Loss) on Investments 6 month | Gain (Loss) on Investments 9 month | Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.15M 10-Q · filed 2026-08-04 | $5.47M 10-Q · filed 2026-08-04 | $7.77M derived: sum of 3 quarters · filed 2026-08-04 | $9.83M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $2.31M 10-Q · filed 2026-05-07 | $4.61M derived: sum of 2 quarters · filed 2026-05-07 | $6.68M derived: sum of 3 quarters · filed 2026-05-07 | $7.83M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $4.37M derived: sum of 2 quarters · filed 2026-02-23 | $5.52M derived: sum of 3 quarters · filed 2026-08-04 | $6.41M 10-K · filed 2026-02-23 |
| 2025-09-30 | $2.07M 10-Q · filed 2025-11-05 | $3.22M derived: sum of 2 quarters · filed 2026-08-04 | $4.11M 10-Q · filed 2025-11-05 | $5.29M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $1.15M 10-Q · filed 2026-08-04 | $2.04M 10-Q · filed 2026-08-04 | $3.23M derived: sum of 3 quarters · filed 2026-08-04 | $5.03M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $887.00K 10-Q · filed 2026-05-07 | $2.07M derived: sum of 2 quarters · filed 2026-05-07 | $3.87M derived: sum of 3 quarters · filed 2026-05-07 | $5.76M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $2.98M derived: sum of 2 quarters · filed 2026-02-23 | $4.88M derived: sum of 3 quarters · filed 2026-02-23 | $7.97M 10-K · filed 2026-02-23 |
| 2024-09-30 | $1.80M 10-Q · filed 2025-11-05 | $3.69M derived: sum of 2 quarters · filed 2025-11-05 | $6.79M 10-Q · filed 2025-11-05 | $7.27M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $1.89M 10-Q · filed 2025-08-05 | $4.99M 10-Q · filed 2025-08-05 | $5.47M derived: sum of 3 quarters · filed 2026-02-23 | $5.51M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $3.10M 10-Q · filed 2025-05-12 | $3.58M derived: sum of 2 quarters · filed 2026-02-23 | $3.62M derived: sum of 3 quarters · filed 2026-02-23 | $3.56M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $484.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $519.00K derived: sum of 2 quarters · filed 2026-02-23 | $458.00K derived: sum of 3 quarters · filed 2026-02-23 | $1.13M 10-K · filed 2026-02-23 |
| 2023-09-30 | $35.00K 10-Q · filed 2024-11-12 | -$26.00K derived: sum of 2 quarters · filed 2024-11-12 | $647.00K 10-Q · filed 2024-11-12 | -$3.17M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$61.00K 10-Q · filed 2024-08-12 | $612.00K 10-Q · filed 2024-08-12 | -$3.20M derived: sum of 3 quarters · filed 2025-03-03 | -$2.34M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $673.00K 10-Q · filed 2024-05-09 | -$3.14M derived: sum of 2 quarters · filed 2025-03-03 | -$2.28M derived: sum of 3 quarters · filed 2025-03-03 | -$4.08M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$3.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$2.96M derived: sum of 2 quarters · filed 2025-03-03 | -$4.76M derived: sum of 3 quarters · filed 2025-03-03 | -$3.09M 10-K · filed 2025-03-03 |
| 2022-09-30 | $857.00K 10-Q · filed 2023-11-09 | -$943.00K derived: sum of 2 quarters · filed 2023-11-09 | $723.00K 10-Q · filed 2023-11-09 | -$6.20M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-06-30 | -$1.80M 10-Q · filed 2023-08-08 | -$134.00K 10-Q · filed 2023-08-08 | -$7.06M derived: sum of 3 quarters · filed 2024-03-19 | -$13.00M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-03-31 | $1.67M 10-Q · filed 2023-05-11 | -$5.26M derived: sum of 2 quarters · filed 2024-03-19 | -$11.20M derived: sum of 3 quarters · filed 2024-03-19 | -$11.38M derived: sum of 4 quarters · filed 2024-03-19 |
| 2021-12-31 | -$6.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$12.87M derived: sum of 2 quarters · filed 2024-03-19 | -$13.04M derived: sum of 3 quarters · filed 2024-03-19 | -$4.10M 10-K · filed 2024-03-19 |
| 2021-09-30 | -$5.94M 10-Q · filed 2022-11-09 | -$6.12M derived: sum of 2 quarters · filed 2022-11-09 | $2.83M 10-Q · filed 2022-11-09 | $4.05M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$177.00K 10-Q · filed 2022-08-08 | $8.77M 10-Q · filed 2022-08-08 | $9.99M derived: sum of 3 quarters · filed 2023-03-01 | $10.14M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $8.94M 10-Q · filed 2022-05-10 | $10.17M derived: sum of 2 quarters · filed 2023-03-01 | $10.31M derived: sum of 3 quarters · filed 2023-03-01 | $11.30M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $1.37M derived: sum of 2 quarters · filed 2023-03-01 | $2.36M derived: sum of 3 quarters · filed 2023-03-01 | $2.44M 10-K · filed 2023-03-01 |
| 2020-09-30 | $149.00K 10-Q · filed 2021-11-12 | $1.14M derived: sum of 2 quarters · filed 2021-11-12 | $1.21M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $986.00K 10-Q · filed 2021-08-12 | $1.06M 10-Q · filed 2021-08-12 | ||
| 2019-12-31 | $2.44M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |